Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
132.00
+4.00 (3.13%)
May 15, 2026, 1:30 PM CST
Market Cap21.44B -19.7%
Revenue (ttm)31.42M -8.5%
Net Income-356.04M
EPS-2.13
Shares Out167.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume184,202
Average Volume244,907
Open128.50
Previous Close128.00
Day's Range127.00 - 135.00
52-Week Range121.00 - 329.50
Beta0.22
RSI45.26
Earnings DateMay 18, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. L... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 39
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Financial Statements